reports
- ABGSC Healthcare Research
- Alexander Krämer
- Georg Tigalonov-Bjerke
Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform ...
Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at PEGS Europe OSLO, Norway, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced new findings related to its APC-targeted inverse vaccine platform’s efficacy in treating autoimmune disease at the annual PEGS Europe conference in Barcelona. The data presented emphasize the role of antigen-presenting cell (APC) targeting in achieving therapeutic effectiveness, particularly...
- Geir Hiller Holom
Nykode Therapeutics (Buy, TP: NOK21.00) - It’s all about the partners
Following the decision to discontinue the C-04 trial, we expect limited value from data within the guided runway. We continue to like the technology’s outlook and believe partnerships could create material shareholder value short- to mid-term. We reiterate our BUY, but have cut our target price to NOK21 (31).
- ABGSC Healthcare Research
- Alexander Krämer
- Georg Tigalonov-Bjerke
- Geir Hiller Holom
Nykode Therapeutics (Buy, TP: NOK31.00) - Q2 report and C-04 discontin...
The company announced it has decided to discontinue the C-04 trial based on standard-of-care changes and feedback from key opinion leaders. Regarding the recently announced Genentech reorganisation, it said that it has “not received any indications of the partnership being affected”.
- ABGSC Healthcare Research
- Alexander Krämer
Nykode Therapeutics Announces Issuance of Key Patent Covering Individu...
Nykode Therapeutics Announces Issuance of Key Patent Covering Individualized Neoantigen Based Vaccines OSLO, Norway, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,059,459, entitled, “Therapeutic Anticancer Neoepitope Vaccine”. The newly issued patent describes Nykode’s fully individualized neoantigen based vaccine, VB10.NEO, which is in develop...
Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform ...
Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting OSLO, Norway, June 20, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced advancements in its inverse vaccine platform at the annual Federation of Clinical Immunology Societies (FOCIS) meeting in San Francisco. Building on findings previously announced in March at the Antigen-Specific Immune Tolerance Summit in Boston, Nykode presented extended therapeutic data...
- ABGSC Healthcare Research
- Alexander Krämer
Nykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Sup...
Nykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy OSLO, Norway, June 11, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced updates on its mRNA platform at the Cancer Immunotherapy meeting in Boston. The company highlighted the significant advantages of its innovative APC-targeted neoantigen vaccine, delivered in a mRNA-lipid nanoparticle (LNP) format. This latest study demonstrated that the APC-targeted va...
- Geir Hiller Holom
Nykode Therapeutics (Buy, TP: NOK31.00) - Q1 report and Merck collabor...
While the Q1 report contained no large surprises (the expected upcoming events near-term seem on track), the company also announced a collaboration with MSD (Merck) to evaluate VB10.16 in combination with KEYTRUDA (pembrolizumab) in patients with HPV16-associated high-risk locally advanced cervical cancer. Management is due to present the results at a live-streamed webcast at 16:00 CET today.
- ABGSC Healthcare Research
- Alexander Krämer
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evalu...
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer OSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that it has expanded its collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) to include a clinical trial collaboration and supply agreement for a phase 2 trial evaluating N...
Nykode Therapeutics - Quarterly report Q1 2024
Nykode Therapeutics - Quarterly report Q1 2024 OSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced its unaudited financial results for the first quarter of 2024. The financial report can be accessed in the Investors section of the Company’s website: . The Company will host a webcast presentation at 4 p.m. CET / 10 a.m. ET. A live and archived webcast of the presentation can be accessed in the Investors section of the ...
Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line ...
Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer OSLO, Norway, April 19, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced the initiation of the Phase 2 clinical trial VB-C-04. The trial evaluates VB10.16, the company’s off-the-shelf therapeutic cancer vaccine candidate for HPV16-positive cancers, alone or in combination with Roche’s checkpoint inhibitor atezolizumab (Tecentriq®1) in patients with HP...
Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged ...
Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer Updated survival data from Phase 2 trial (C-02) in advanced cervical cancer affirm prolonged benefits and indicate a synergistic treatment effect of Nykode’s VB10.16 and atezolizumab (Tecentriq®).New analysis closely mirrors previously reported positive outcome. At the time of the updated analysis, observation time for remaining patients was at least 24 months compared to at least 12 months at the previous reported outcome. ...
Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform...
Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune Diseases OSLO, Norway, March 19, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced key updates of the inverse vaccine platform with the potential to treat autoimmune diseases at the 7th Antigen-Specific Immune Tolerance Drug Development Summit in Boston. Nykode employs its unique technology platform to pioneer the field of inverse vaccines, w...
- Geir Hiller Holom
Nykode Therapeutics (Buy, TP: NOK31.00) - Realign the map with the ter...
We still like the long-term outlook (far more than the market is pricing in), and have high expectations for 2024. We reiterate our BUY, but have cut our target price to NOK31 (102) as despite our generally unchanged fundamental view, we see a lower market perception on the value of the pipeline assets, especially as the Genentech partnership represents most of our valuation.
Nykode Therapeutics - Quarterly report Q3 2023
Nykode Therapeutics - Quarterly report Q3 2023 OSLO, Norway, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced its unaudited financial results for the third quarter of 2023. The financial report can be accessed in the Investors section of the Company’s website: The Company will host a webcast presentation at 4 p.m. CET / 10 a.m. ET. A live and archived webcast of the presentation can be accessed in the Investors section of the Company’...
- Geir Hiller Holom
Nykode Therapeutics (Buy, TP: NOK102.00) - Estimates not updatedEstima...
Nykode must settle a tax payable estimated at USD30m (we speculate during Q4 2023) following a formal decision by the Norwegian Tax Administration yesterday. The tax issue was announced in the 2022 annual report and the decision therefore does not come as a large surprise – but we only see a limited impact.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.